Profile: Merck & Co., Inc. provides novel medicines and vaccines. Our glycofi's proprietary technology is based on a library of yeast strains that have been engineered to perform specific human glycosylation at high fidelity. Our glycofi's glycoengineered yeast strains have been optimized to produce proteins with one particular glycoform at high uniformity. By expressing a given protein in different glycoengineered yeast strains glycofi can generate a library of glycoproteins, all with identical peptide backbone but with different sugar structures attached to them. This allows for the identification of the glycoform with the highest therapeutic potency and creates opportunities to optimize a drug's therapeutic profile. This technology can be broadly applied to all glycoproteins, including growth factors, fusion proteins & monoclonal antibodies.